Shares of Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) were up 15.8% during trading on Monday . The company traded as high as $3.00 and last traded at $2.34, with a volume of 1,383,266 shares traded. The stock had previously closed at $2.02.

A number of analysts recently commented on EYEG shares. Noble Financial assumed coverage on Eyegate Pharmaceuticals in a research report on Thursday, April 7th. They issued a “buy” rating and a $10.00 price objective for the company. Chardan Capital restated a “buy” rating on shares of Eyegate Pharmaceuticals in a report on Thursday, April 14th. Maxim Group restated a “buy” rating on shares of Eyegate Pharmaceuticals in a report on Tuesday, April 26th. Finally, Rodman & Renshaw restated a “buy” rating on shares of Eyegate Pharmaceuticals in a report on Thursday, May 12th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $9.00.

The firm’s market cap is $17.19 million. The firm’s 50-day moving average is $2.59 and its 200-day moving average is $3.00.

In related news, major shareholder Ventech Capital Ii sold 28,600 shares of the company’s stock in a transaction on Friday, June 10th. The stock was sold at an average price of $3.04, for a total transaction of $86,944.00. Following the completion of the sale, the insider now directly owns 1,608,973 shares in the company, valued at approximately $4,891,277.92. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Morton Goldberg sold 10,939 shares of the company’s stock in a transaction on Tuesday, June 7th. The stock was sold at an average price of $3.31, for a total value of $36,208.09. Following the sale, the director now owns 43,216 shares of the company’s stock, valued at $143,044.96. The disclosure for this sale can be found here.

Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.